Harpoon Therapeutics 将来の成長
Future 基準チェック /26
Harpoon Therapeutics is forecast to grow earnings and revenue by 10.6% and 35.3% per annum respectively. EPS is expected to grow by 25.7% per annum. Return on equity is forecast to be -220.2% in 3 years.
主要情報
10.6%
収益成長率
25.7%
EPS成長率
Biotechs 収益成長 | 27.1% |
収益成長率 | 35.3% |
将来の株主資本利益率 | -220.2% |
アナリストカバレッジ | Good |
最終更新日 | 11 Mar 2024 |
今後の成長に関する最新情報
Recent updates
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified
Jan 30Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough
Oct 01Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Aug 14Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically
May 28Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 47 | -76 | -67 | -94 | 5 |
12/31/2025 | 23 | -67 | -54 | -64 | 8 |
12/31/2024 | 21 | -56 | -33 | -51 | 8 |
12/31/2023 | 38 | -26 | -16 | -40 | 8 |
9/30/2023 | 37 | -30 | -69 | -69 | N/A |
6/30/2023 | 47 | -40 | -77 | -77 | N/A |
3/31/2023 | 35 | -59 | -84 | -83 | N/A |
12/31/2022 | 32 | -68 | -90 | -89 | N/A |
9/30/2022 | 32 | -71 | -88 | -88 | N/A |
6/30/2022 | 23 | -76 | -84 | -84 | N/A |
3/31/2022 | 21 | -75 | -129 | -129 | N/A |
12/31/2021 | 24 | -117 | -122 | -122 | N/A |
9/30/2021 | 27 | -107 | -121 | -120 | N/A |
6/30/2021 | 26 | -103 | -114 | -113 | N/A |
3/31/2021 | 23 | -99 | -10 | -9 | N/A |
12/31/2020 | 17 | -50 | -9 | -9 | N/A |
9/30/2020 | 12 | -53 | 39 | 40 | N/A |
6/30/2020 | 10 | -55 | 40 | 43 | N/A |
3/31/2020 | 8 | -55 | -11 | -8 | N/A |
12/31/2019 | 6 | -56 | -6 | -3 | N/A |
9/30/2019 | 5 | -51 | -46 | -43 | N/A |
6/30/2019 | 4 | -42 | -41 | -39 | N/A |
3/31/2019 | 4 | -36 | -33 | -32 | N/A |
12/31/2018 | 5 | -27 | -28 | -27 | N/A |
9/30/2018 | 4 | -23 | -9 | -8 | N/A |
12/31/2017 | 1 | -17 | -1 | 2 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: HARP is forecast to remain unprofitable over the next 3 years.
収益対市場: HARP is forecast to remain unprofitable over the next 3 years.
高成長収益: HARP is forecast to remain unprofitable over the next 3 years.
収益対市場: HARP's revenue (35.3% per year) is forecast to grow faster than the US market (8.1% per year).
高い収益成長: HARP's revenue (35.3% per year) is forecast to grow faster than 20% per year.
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: HARP is forecast to be unprofitable in 3 years.